Ankur Drugs & Pharma
Ankur Drugs & Pharma
HealthcareTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has reduced debt.
- Stock is trading at 0.03 times its book value
Weaknesses
5- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -16.5% over past five years.
- Company has a low return on equity of -17.1% over last 3 years.
- Company might be capitalizing the interest cost
- Debtor days have increased from 37.4 to 76.5 days.
Growth Rate
Quarterly Results
| Particulars | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 19.48 | 14.27 | 16.74 | 14.29 | 13.6 | 12.62 | 13.87 | 13.04 | 11.03 | 11.08 | 12.71 | 14.43 | 14.78 |
| Expenses | 22.6 | 15.36 | 18.11 | 14.83 | 15.59 | 13.01 | 16.24 | 14.06 | 11.34 | 10.09 | 16.35 | 15.82 | 15.04 |
| Operating Profit | -3.12 | -1.09 | -1.37 | -0.54 | -1.99 | -0.39 | -2.37 | -1.02 | -0.31 | 0.99 | -3.64 | -1.39 | -0.26 |
| OPM % | -16.02% | -7.64% | -8.18% | -3.78% | -14.63% | -3.09% | -17.09% | -7.82% | -2.81% | 8.94% | -28.64% | -9.63% | -1.76% |
| Other Income | 1.19 | 1.11 | 1.1 | 1.14 | 2.66 | 1.4 | 1.35 | 1.32 | 1.03 | 1.11 | 1.12 | 1.11 | 2.06 |
| Interest | 0.43 | 0.32 | 0.23 | 0.27 | 0.48 | 0.19 | 0.22 | 0.2 | 0.45 | 0.14 | 0.25 | 0.17 | 0.64 |
| Depreciation | -0.06 | 0.17 | 0.18 | 0.17 | 0.26 | 0.19 | 0.18 | 0.29 | 0.11 | 0.18 | 0.24 | 0.22 | -0.11 |
| PBT | -2.3 | -0.47 | -0.68 | 0.16 | -0.07 | 0.63 | -1.42 | -0.19 | 0.16 | 1.78 | -3.01 | -0.67 | 1.27 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -2.3 | -0.47 | -0.68 | 0.16 | -0.07 | 0.63 | -1.42 | -0.19 | 0.16 | 1.78 | -3.01 | -0.67 | 1.27 |
Profit & Loss
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
|---|---|---|---|---|---|---|---|
| Sales | 135 | 373 | 674 | 965 | 1,067 | 825 | 151 |
| Expenses | 113 | 315 | 567 | 833 | 860 | 690 | 176 |
| Operating Profit | 22 | 58 | 107 | 132 | 207 | 135 | -25 |
| OPM % | 16% | 16% | 16% | 14% | 19% | 16% | -16% |
| Other Income | 0 | 0 | 2 | 2 | 20 | 0 | -144 |
| Interest | 4 | 13 | 25 | 54 | 81 | 121 | 58 |
| Depreciation | 2 | 6 | 8 | 21 | 27 | 61 | 61 |
| PBT | 15 | 39 | 75 | 59 | 120 | -47 | -288 |
| Tax % | 9% | 17% | 15% | 37% | 28% | 47% | 7% |
| Net Profit | 14 | 33 | 64 | 37 | 86 | -69 | -307 |
| EPS in Rs | — | 31.01 | 50 | 19.95 | 44.56 | -35.58 | -159 |
| Div. Payout % | 10% | 6% | 4% | 11% | 5% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 11 | 13 | 19 | 19 | 19 | 19 |
| Reserves | 19 | 103 | 207 | 253 | 338 | 269 | 219 |
| Borrowings | 111 | 352 | 618 | 745 | 950 | 1,157 | 857 |
| Other Liabilities | 16 | 40 | 62 | 118 | 566 | 334 | 434 |
| Total Liabilities | 156 | 505 | 900 | 1,135 | 1,873 | 1,779 | 1,529 |
| Fixed Assets | 33 | 112 | 204 | 346 | 704 | 1,220 | 1,159 |
| CWIP | 66 | 245 | 331 | 266 | 786 | 285 | 266 |
| Investments | 0 | 0 | 5 | 4 | 0 | 0 | 0 |
| Other Assets | 58 | 148 | 359 | 519 | 383 | 275 | 103 |
| Total Assets | 156 | 505 | 900 | 1,135 | 1,873 | 1,779 | 1,529 |
Cash Flow
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
|---|---|---|---|---|---|---|---|
| Operating | 8 | 23 | 22 | 42 | 844 | -41 | 3 |
| Investing | -59 | -188 | -191 | -94 | -938 | -92 | 24 |
| Financing | 53 | 165 | 226 | 9 | 88 | 130 | -27 |
| Net Cash Flow | 1 | 0 | 56 | -43 | -6 | -2 | 0 |
| Free Cash Flow | -52 | -165 | -165 | -55 | -61 | -117 | 11 |
| CFO/OP | 38 | 45 | 29 | 36 | 416 | -26 | -18 |
Ratios
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 76 | 75 | 89 | 106 | 19 | 17 | 77 |
| Inventory Days | 86 | 77 | 83 | 105 | 120 | 98 | 57 |
| Days Payable | 19 | 31 | 24 | 28 | 207 | 85 | 478 |
| Cash Conversion Cycle | 144 | 121 | 148 | 183 | -68 | 29 | -344 |
| Working Capital Days | 119 | 109 | 134 | 154 | -67 | -14 | -722 |
| ROCE % | — | 17% | 15% | 12% | 17% | 5% | -7% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Ankur Drugs & Pharma insights
51 extracted metrics + investor summaries across FY06–FY12.
Documents
Frequently Asked Questions about Ankur Drugs & Pharma
What does Ankur Drugs & Pharma Ltd do?
Which sector does Ankur Drugs & Pharma Ltd belong to?
Company Information
Ankur Drugs & Pharma Limited, incorporated in India, Listed on the Bombay Stock exchange Limited, and National Stock Exchange Limited, the company is engaged in Pharmaceutical Formulations
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ANKURDRUGS.md for Ankur Drugs & Pharma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.